Kindred Biosciences Announces the Termination of Its At-The-Market Equity Offering Program

SAN FRANCISCO, June 20, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced the termination of its "at-the-market" equity offering program (the "ATM Facility") with B....